Skip Navigation Links
Review of Shanghai Junshi (1877.HK)
10 Jan 2023 (283 views)  

I bought 5,000 shares of Shanghai Junshi (1877.HK) at $41.65 HKD on 9 Jan. The price jumped by 7.7% to $45.00 within one day. 

I bought this stock because it produced the VV116 theraphy for covid that is more effective than Paxlovid. They have applied for approval of this drug, and are waiting for the decision. 

Report

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announces the online publication in New England Journal (NEJM) of the Phase 3 trial (NCT05341609) comparing the efficacy and safety of VV116 (JT001) and nirmatrelvir/ritonavir (“PAXLOVID”) in the treatment of symptomatic patients with mild to moderate COVID-19 who are at high risk for progression to severe COVID-19 including death. It is the first time that NEJM published the clinical trial results of China-developed anti-SARS-CoV-2 drug.

The study, led by Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, is the first “head-to-head” phase III clinical study of small molecule oral anti-SARS-CoV drug in Chinese COVID-19 patients during the Omicron outbreak. The results indicated that the primary endpoint of the study realized the designed noninferiority endpoint, and VV116 group had a shorter time to sustained clinical recovery with less safety concerns as compared with PAXLOVID.

The company is still operating at a loss.  The future profit depends on the approval of VV116 and its sales.

In November 2021, the US government paid $5.3 billion for 10 million courses of Paxlovid. This works out to US $530 for a 5 day course. It implies a large profit margin to the manufacturer Pfizer.

Shanghai Junshi should be able to sell VV116 at a lower price, gain a large market share and show a huge profit.

I read from other reports that Shanghai Junshi had also developed therapies for the treatment of cancer and have entered into marketing arrangements to sell the therapies.

I will study them in more detail. 

Note - this is my finding on the stock. I am not giving investment advice.

Tan Kin Lian


 

Review of Shanghai Junshi (1877.HK)
[Back] [Print]


I bought 5,000 shares of Shanghai Junshi (1877.HK) at $41.65 HKD on 9 Jan. The price jumped by 7.7% to $45.00 within one day. 

I bought this stock because it produced the VV116 theraphy for covid that is more effective than Paxlovid. They have applied for approval of this drug, and are waiting for the decision. 

Report

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announces the online publication in New England Journal (NEJM) of the Phase 3 trial (NCT05341609) comparing the efficacy and safety of VV116 (JT001) and nirmatrelvir/ritonavir (“PAXLOVID”) in the treatment of symptomatic patients with mild to moderate COVID-19 who are at high risk for progression to severe COVID-19 including death. It is the first time that NEJM published the clinical trial results of China-developed anti-SARS-CoV-2 drug.

The study, led by Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, is the first “head-to-head” phase III clinical study of small molecule oral anti-SARS-CoV drug in Chinese COVID-19 patients during the Omicron outbreak. The results indicated that the primary endpoint of the study realized the designed noninferiority endpoint, and VV116 group had a shorter time to sustained clinical recovery with less safety concerns as compared with PAXLOVID.

The company is still operating at a loss.  The future profit depends on the approval of VV116 and its sales.

In November 2021, the US government paid $5.3 billion for 10 million courses of Paxlovid. This works out to US $530 for a 5 day course. It implies a large profit margin to the manufacturer Pfizer.

Shanghai Junshi should be able to sell VV116 at a lower price, gain a large market share and show a huge profit.

I read from other reports that Shanghai Junshi had also developed therapies for the treatment of cancer and have entered into marketing arrangements to sell the therapies.

I will study them in more detail. 

Note - this is my finding on the stock. I am not giving investment advice.

Tan Kin Lian